FDA slaps a full clinical hold on Alcobra’s troubled lead drug for ADHD, Fragile X
Following a series of clinical setbacks and missteps, Alcobra $ADHD says its lead drug MDX has been put on a full clinical hold by the FDA “due to adverse neurological findings in a pre-clinical study.”
The hold will stop its ongoing Phase III study in adult patients with ADHD, according to the Israeli biotech, which reported at the end of August that it had recruited 474 patients for the study.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.
